<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00143351</url>
  </required_header>
  <id_info>
    <org_study_id>A1281088</org_study_id>
    <nct_id>NCT00143351</nct_id>
  </id_info>
  <brief_title>Mozart Relapse Study</brief_title>
  <official_title>Open Extension Study Evaluating the Long-Term Efficacy, Safety, and Tolerability of Oral Ziprasidone in the Treatment of Resistant/Intolerant Schizophrenic Patients Who Have Acutely Responded to Ziprasidone in the Mozart Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <brief_summary>
    <textblock>
      To assess the long-term efficacy of oral Ziprasidone in the maintenance treatment of
      resistant schizophrenic subjects who have benefited from participation in the phase III
      ziprasidone study A1281039 (MOZART study), to assess the efficacy of ziprasidone in the
      relapse prevention of schizophrenia, to collect long-term data on safety and tolerability of
      oral Ziprasidone
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date>September 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>long-term efficacy of oral Ziprasidone in the maintenance treatment</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the efficacy of ziprasidone in the relapse prevention of schizophrenia To collect long-term data on safety and tolerability of oral Ziprasidone</measure>
  </secondary_outcome>
  <enrollment>75</enrollment>
  <condition>Schizophrenia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ziprasidone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who have completed MOZART study and who are responders to Ziprasidone:

          -  Responders: patients with a 20% or more reduction in the PANSS total score at the
             endpoint of the Mozart Study (recorded at V18 in the Mozart) as compared with the
             baseline value

          -  Patients not hospitalised in an acute psychiatric service

          -  Written, informed consent to participation.

          -  Female patients of at risk of pregnancy must avoid to remain pregnant; if already
             used, an adequate method of contraception can be continued

        Exclusion Criteria:

          -  Psychiatric:

          -  Subjects with a score of greater than or equal to 5 and an increase of at least 2
             points (with respect to baseline value of MOZART study) at one of the following PANSS
             items: P7 (hostility), G8 (uncooperativeness) or G14 (poor control impulse)

          -  Subjects with a score equal to 3 and an increase of at least 1 point (with respect to
             baseline value of MOZART study) at item 8 (suicide) of CDSS

          -  General:

          -  Patients who, during MOZART study, have developed one of the following diseases will
             be excluded: (or patients who do not satisfy anymore one of the following general
             exclusion criteria of MOZART study)

          -  Subjects with a history of clinically significant and/or currently relevant
             haematological, renal (including single kidney), hepatic, gastrointestinal, endocrine
             (except for current adequately treated hypo- or hyperthyroidism), pulmonary (excluding
             chronic bronchitis, mild emphysema or chronic obstructive pulmonary disease),
             dermatological, oncological, or neurological disease, excluding tardive dyskinesia but
             including all forms of epilepsy (febrile convulsions in childhood acceptable). The
             only subjects with known prior malignant disease who are eligible are those with cured
             prior skin cancer. Controlled Type II diabetes (glucose &lt; 180 mg/100 ml at screening
             and baseline with dietary or oral hypoglycemic treatment) will not be considered a
             significant medical illness and would not exclude a subject from the study

          -  Patients with a non stabilized somatic disease - Acute or chronic heart disease

          -  Clinically significant ECG abnormalities

          -  Subjects with QTc greater than or equal to 500 msec (subjects with QTc greater than or
             equal to 450 msec and &lt; 500 msec should be discussed with the cardiologist) -
             Concomitant treatment with medications that prolong QTc interval (please review
             prescribing information of other treatments)

          -  Subjects with serum K+ outside the normal range

          -  History of seizure (should be discussed with the Sponsor)

          -  Subject with any confirmed laboratory values that deviate from the upper or lower
             limits of normal prior to study entry, except for clinically insignificant deviations
             as determined by investigator

          -  Pregnant or lactating women

          -  Subjects who intend to donate blood or blood products during the 4 weeks prior to the
             study, during the study or in the 30 days after the study ends

          -  Subjects unable or unlikely to follow the study protocol

          -  Subjects with a history of neuroleptic malignant syndrome developing from the
             administration of antipsychotic compounds

          -  Diagnosis of substance dependence using DSM-IV criteria (305.xx)

          -  Positive urine drug screen at screening for amphetamines, cocaine or opioids
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Vicenza</city>
        <state>Bassano Del Grappa</state>
        <zip>36061</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Citta' Di Castello</city>
        <state>Perugia</state>
        <zip>06012</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bari</city>
        <zip>70100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Brescia</city>
        <zip>25100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Catania</city>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Guardiagrele (ch)</city>
        <zip>66016</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Messina</city>
        <zip>98100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Parma</city>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Roma</city>
        <zip>00100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Roma</city>
        <zip>00135</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Roma</city>
        <zip>00137</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sassari</city>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Terni</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Trieste</city>
        <zip>34126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Verona</city>
        <zip>37100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2005</study_first_submitted>
  <study_first_submitted_qc>August 31, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2005</study_first_posted>
  <last_update_submitted>December 28, 2006</last_update_submitted>
  <last_update_submitted_qc>December 28, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 1, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ziprasidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

